Armata wins FDA agreement on pediatric study plan for AP-SA02 in complicated S. aureus bacteremia

Innoviva, Inc.
Armata Pharmaceuticals

Innoviva, Inc.

INVA

0.00

Armata Pharmaceuticals

ARMP

0.00
  • Armata Pharmaceuticals secured FDA agreement on an initial pediatric study plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
  • The milestone supports a future biologics license application for AP-SA02.
  • Pediatric trials were deferred until adult Phase 3 data; the adult study is expected to start in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607130700PR_NEWS_USPR_____LA02587) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.